Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 174
People’s Research Agenda
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.
Prevention Option:
HIV Prevention Pipeline: Products to Watch
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
Prevention Option:
People’s Research Agenda Pipeline Tracker
This tracker provides details on key HIV prevention trials to watch. It is updated on a quarterly and ad-hoc basis as developments occur.
Prevention Option:
People’s Research Agenda 2025 Update Summary Table
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
Prevention Option:
From The Lab To The Jab: Lessons learned and what’s next in HIV vaccine research
On 3 June 2024, AVAC hosted a webinar highlighting its Lab to Jab issue briefs on research and development, production and equitable global access to vaccines. Platforms, Not Pathogens Panelists stressed an intentional, rather than incidental...
Prevention Option:
Top Vaccines Funders
Total US dollars invested by each of the top 10 global funders of vaccine research in 2022.
Prevention Option:
The Years Ahead in Biomedical HIV Prevention Research
[[DRAFT; UNPUBLISHED]] This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Vaccine Development History
A graphic showing the duration between discovery of the microbiologic cause of selected infectious diseases and the development of a vaccine.
Prevention Option:
showing 1-10 of 174